Farallon Capital Management, L.L.C. is an SEC-registered investment adviser based in San Francisco, CA that reports managing 50 hedge funds on Form ADV. It reports $52.1 billion in regulatory assets under management. Its private funds, of all types, hold $64.5 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +16.2% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +49.1% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $52.1 billionForm ADV Item 5.F
- Gross assets of private funds
- $64.5 billionAll private fund types, Form ADV
- Hedge funds managed
- 5050 private funds in total
- Employees
- 355Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 107322
- Latest Form ADV
- 09/23/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +23.6% | +14.8% |
| Q1 2026 | -6.1% | -4.6% |
| Q4 2025 | +8.0% | +2.4% |
| Q3 2025 | +4.7% | +7.8% |
| Q2 2025 | +6.8% | +10.4% |
| Q1 2025 | -4.2% | -4.5% |
| Q4 2024 | -0.3% | +2.1% |
| Q3 2024 | +11.3% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 110 share positions ($18,657,509,328) reported by Farallon Capital Management, L.L.C. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Revolution Medicines Inc14.76%
- Warner Bros Discovery Inc8.19%
- Natera Inc5.76%
- Bridgebio Pharma Inc5.02%
- Protagonist Therapeutics Inc4.86%
- Exelixis Inc4.60%
- Roivant Sciences LTD4.26%
- Roku Inc3.40%
- Amazon Com Inc3.16%
- Grail Inc3.06%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Revolution Medicines Inc | $2,754,342,067 | 14.76% | 13,418,796 | -0.97% |
| Warner Bros Discovery Inc | $1,528,074,047 | 8.19% | 49,372,344 | New |
| Natera Inc | $1,074,460,515 | 5.76% | 2,599,648 | +17.19% |
| Bridgebio Pharma Inc | $937,452,600 | 5.02% | 14,247,000 | +32.62% |
| Protagonist Therapeutics Inc | $907,036,576 | 4.86% | 6,437,906 | +1.40% |
| Exelixis Inc | $858,329,693 | 4.60% | 14,694,910 | +9.11% |
| Roivant Sciences LTD | $795,234,142 | 4.26% | 21,745,533 | +51.97% |
| Roku Inc | $633,492,262 | 3.40% | 4,160,049 | New |
| Amazon Com Inc | $590,102,806 | 3.16% | 2,368,464 | -10.05% |
| Grail Inc | $570,180,928 | 3.06% | 4,069,233 | -2.22% |
| Boston Scientific Corp | $492,684,709 | 2.64% | 11,287,164 | +7.28% |
| Broadcom Inc | $490,194,514 | 2.63% | 1,395,810 | +21.19% |
| CRH PLC | $442,243,080 | 2.37% | 5,341,100 | New |
| Kenvue Inc | $441,764,900 | 2.37% | 25,015,000 | New |
| Twist Bioscience Corp | $412,837,936 | 2.21% | 2,136,400 | Unchanged |
| Unitedhealth Group Inc | $384,928,164 | 2.06% | 1,048,622 | -17.47% |
| Microsoft Corp | $376,244,463 | 2.02% | 733,563 | -34.08% |
| Synopsys Inc | $373,130,677 | 2.00% | 857,890 | +3.41% |
| KKR & Co Inc | $354,245,826 | 1.90% | 3,880,020 | -5.79% |
| Aon PLC | $343,104,019 | 1.84% | 1,239,672 | -10.34% |
| Lantheus Hldgs Inc | $309,663,111 | 1.66% | 3,111,254 | -44.28% |
| Thermo Fisher Scientific Inc | $300,859,659 | 1.61% | 445,685 | -57.52% |
| Liquidia Corporation | $269,496,710 | 1.44% | 8,906,038 | +6.47% |
| Wabtec | $252,116,184 | 1.35% | 877,903 | -1.86% |
| Beam Therapeutics Inc | $251,257,882 | 1.35% | 10,276,396 | +0.39% |
| Aramark | $246,674,380 | 1.32% | 4,606,431 | +27.05% |
| Immunovant Inc | $218,590,380 | 1.17% | 6,471,000 | +11.47% |
| Agios Pharmaceuticals Inc | $197,485,050 | 1.06% | 5,939,400 | +0.37% |
| Biogen Inc | $153,794,464 | 0.82% | 680,868 | +858.97% |
| Johnson & Johnson | $127,187,979 | 0.68% | 480,426 | +17.75% |
| Acadia Healthcare Company In | $126,731,000 | 0.68% | 4,608,400 | +9.18% |
| Brightspring Health Svcs Inc | $115,985,650 | 0.62% | 2,043,800 | +17.95% |
| Tango Therapeutics Inc | $113,539,666 | 0.61% | 4,550,688 | -62.93% |
| Baidu Inc | $104,572,803 | 0.56% | 1,203,785 | Unchanged |
| American Svgs BK Na | $81,526,197 | 0.44% | 4,557,082 | New |
| Parabilis Medicines Inc | $76,469,178 | 0.41% | 2,368,200 | Unchanged |
| Astrazeneca PLC | $71,046,800 | 0.38% | 440,000 | -23.34% |
| Joyy Inc | $65,821,050 | 0.35% | 820,200 | +17.31% |
| Avalo Therapeutics Inc | $60,921,420 | 0.33% | 3,974,000 | +59.09% |
| Freenome Inc | $58,806,673 | 0.32% | 3,733,757 | New |
| Ionic Digital Inc | $57,686,821 | 0.31% | 718,123 | New |
| Guardant Health Inc | $49,887,292 | 0.27% | 279,700 | -13.19% |
| Assembly Biosciences Inc | $37,691,819 | 0.20% | 1,604,590 | Unchanged |
| Novartis AG | $36,355,350 | 0.19% | 255,000 | -29.75% |
| Maze Therapeutics Inc | $30,110,385 | 0.16% | 1,107,814 | Unchanged |
| LB Pharmaceuticals Inc | $28,455,316 | 0.15% | 741,410 | New |
| Immunocore Hldgs PLC | $28,109,120 | 0.15% | 928,000 | New |
| Asml Hldg NV | $24,490,155 | 0.13% | 13,518 | New |
| Rio Tinto PLC | $20,613,719 | 0.11% | 218,899 | +19.31% |
| Alibaba Group Hldg LTD | $20,325,060 | 0.11% | 189,000 | New |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 48 new positions, 20 sold out, 22 increased, 19 reduced and 21 unchanged.
Number of positions (a count, not dollars)
- New positions48
- Increased22
- Unchanged21
- Reduced19
- Sold out20
New positions
| Stock | Value | Shares |
|---|---|---|
| Warner Bros Discovery Inc | $1,528,074,047 | 49,372,344 |
| Roku Inc | $633,492,262 | 4,160,049 |
| CRH PLC | $442,243,080 | 5,341,100 |
| Kenvue Inc | $441,764,900 | 25,015,000 |
| American Svgs BK Na | $81,526,197 | 4,557,082 |
| Freenome Inc | $58,806,673 | 3,733,757 |
| Ionic Digital Inc | $57,686,821 | 718,123 |
| LB Pharmaceuticals Inc | $28,455,316 | 741,410 |
| Immunocore Hldgs PLC | $28,109,120 | 928,000 |
| Asml Hldg NV | $24,490,155 | 13,518 |
| Alibaba Group Hldg LTD | $20,325,060 | 189,000 |
| Electra Therapeutics Inc | $19,125,000 | 1,700,000 |
| Indivior Pharmaceuticals Inc | $16,047,177 | 447,620 |
| Latigo Biotrapeutics Inc | $14,195,000 | 850,000 |
| Scribe Therapeutics Inc | $6,993,900 | 380,000 |
| Cohu Inc | $6,200,740 | 91,000 |
| Entegris Inc | $5,700,220 | 37,000 |
| Braveheart Bio Inc | $5,611,116 | 277,778 |
| Celestica Inc | $5,421,450 | 15,000 |
| Revvity Inc | $5,351,150 | 35,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Electronic Arts Inc | $1,623,814,280 | 7,919,500 |
| Crinetics Pharmaceuticals In | $336,372,047 | 8,989,098 |
| Novo-nordisk A S | $125,554,860 | 2,619,000 |
| Merck & Co Inc | $25,571,500 | 199,000 |
| Warby Parker Inc | $25,121,520 | 828,000 |
| Perceptive Cap Solutions Cor | $24,480,000 | 2,250,000 |
| Axalta Coating SYS LTD | $16,357,160 | 478,000 |
| Beta Bionics Inc | $9,323,650 | 595,000 |
| Scotts Miracle-gro Co | $5,993,680 | 88,000 |
| Waystar Hldg Corp | $5,438,397 | 264,900 |
| Brunswick Corp | $5,138,640 | 61,000 |
| Gentex Corp | $5,028,730 | 199,000 |
| Idexx Labs Inc | $4,737,960 | 9,000 |
| Commercial Metals Co | $4,204,250 | 67,000 |
| Teva Pharmaceutical Inds LTD | $1,355,200 | 40,000 |
| Aleanna Inc | $297,000 | 990,000 |
| Aleanna Inc | $227,360 | 78,400 |
| Solid Power Inc | $41,423 | 405,316 |
| Blue Gold LTD | $30,696 | 255,800 |
| Beyond Meat Inc | $14,250 | 19,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Roivant Sciences LTD | +7,436,533 | +51.97% | $795,234,142 | 21,745,533 |
| Bridgebio Pharma Inc | +3,503,937 | +32.62% | $937,452,600 | 14,247,000 |
| Natera Inc | +381,282 | +17.19% | $1,074,460,515 | 2,599,648 |
| Biogen Inc | +609,868 | +858.97% | $153,794,464 | 680,868 |
| Broadcom Inc | +244,010 | +21.19% | $490,194,514 | 1,395,810 |
| Exelixis Inc | +1,226,900 | +9.11% | $858,329,693 | 14,694,910 |
| Aramark | +980,700 | +27.05% | $246,674,380 | 4,606,431 |
| Boston Scientific Corp | +765,980 | +7.28% | $492,684,709 | 11,287,164 |
| Avalo Therapeutics Inc | +1,476,000 | +59.09% | $60,921,420 | 3,974,000 |
| Immunovant Inc | +666,000 | +11.47% | $218,590,380 | 6,471,000 |
| Johnson & Johnson | +72,426 | +17.75% | $127,187,979 | 480,426 |
| Brightspring Health Svcs Inc | +311,000 | +17.95% | $115,985,650 | 2,043,800 |
| Liquidia Corporation | +541,000 | +6.47% | $269,496,710 | 8,906,038 |
| Protagonist Therapeutics Inc | +89,000 | +1.40% | $907,036,576 | 6,437,906 |
| Synopsys Inc | +28,290 | +3.41% | $373,130,677 | 857,890 |
| Acadia Healthcare Company In | +387,600 | +9.18% | $126,731,000 | 4,608,400 |
| Joyy Inc | +121,000 | +17.31% | $65,821,050 | 820,200 |
| Rio Tinto PLC | +35,424 | +19.31% | $20,613,719 | 218,899 |
| Abivax SA | +18,000 | +14.75% | $13,862,800 | 140,000 |
| Beam Therapeutics Inc | +40,000 | +0.39% | $251,257,882 | 10,276,396 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | -603,500 | -57.52% | $300,859,659 | 445,685 |
| Lantheus Hldgs Inc | -2,472,225 | -44.28% | $309,663,111 | 3,111,254 |
| Microsoft Corp | -379,300 | -34.08% | $376,244,463 | 733,563 |
| Tango Therapeutics Inc | -7,726,312 | -62.93% | $113,539,666 | 4,550,688 |
| Unitedhealth Group Inc | -221,910 | -17.47% | $384,928,164 | 1,048,622 |
| Amazon Com Inc | -264,530 | -10.05% | $590,102,806 | 2,368,464 |
| Aon PLC | -142,890 | -10.34% | $343,104,019 | 1,239,672 |
| Revolution Medicines Inc | -132,000 | -0.97% | $2,754,342,067 | 13,418,796 |
| KKR & Co Inc | -238,280 | -5.79% | $354,245,826 | 3,880,020 |
| Astrazeneca PLC | -134,000 | -23.34% | $71,046,800 | 440,000 |
| Enanta Pharmaceuticals Inc | -1,468,202 | -60.71% | $12,521,000 | 950,000 |
| Novartis AG | -108,000 | -29.75% | $36,355,350 | 255,000 |
| Grail Inc | -92,351 | -2.22% | $570,180,928 | 4,069,233 |
| Guardant Health Inc | -42,500 | -13.19% | $49,887,292 | 279,700 |
| Mobia Med Inc | -690,729 | -61.20% | $4,137,475 | 437,828 |
| Wabtec | -16,600 | -1.86% | $252,116,184 | 877,903 |
| Sagimet Biosciences Inc | -15,000 | -3.61% | $3,952,000 | 400,000 |
| Inflarx NV | -15,000 | -0.45% | $5,958,000 | 3,310,000 |
| Nvni Group Limited | -43,600 | -11.63% | $5,700 | 331,400 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Tango Therapeutics, Inc. | 13G amendment | 4.9% | 8,543,875 | Nov 16, 2026 | SEC.gov ↗ |
| Lantheus Holdings, Inc. | 13G amendment | 4.8% | 3,111,254 | Nov 16, 2026 | SEC.gov ↗ |
| Enanta Pharmaceuticals Inc | 13G amendment | 3.3% | 950,000 | Nov 16, 2026 | SEC.gov ↗ |
| Avalo Therapeutics, Inc. | 13G | 7.4% | 3,974,000 | Nov 13, 2026 | SEC.gov ↗ |
| Crinetics Pharmaceuticals, Inc. | 13G amendment | 0% | 0 | Nov 12, 2026 | SEC.gov ↗ |
| BridgeBio Pharma, Inc. | 13G amendment | 7.3% | 14,247,000 | Nov 12, 2026 | SEC.gov ↗ |
| Exelixis, Inc. | 13G | 6% | 14,694,910 | Nov 9, 2026 | SEC.gov ↗ |
| Tyra Biosciences, Inc. | 13G amendment | 0% | 6,000 | Aug 14, 2026 | SEC.gov ↗ |
| Savara Inc. | 13G amendment | 6.8% | 15,000,000 | Aug 14, 2026 | SEC.gov ↗ |
| InflaRx N.V. | 13G amendment | 2.3% | 3,325,000 | Aug 14, 2026 | SEC.gov ↗ |
| Revolution Medicines, Inc. | 13G amendment | 6.4% | 13,564,149 | Aug 13, 2026 | SEC.gov ↗ |
| Protagonist Therapeutics, Inc. | 13G amendment | 9.99% | 6,433,119 | Aug 13, 2026 | SEC.gov ↗ |
| Minerva Neurosciences, Inc. | 13G amendment | 9.7% | 4,730,000 | Aug 13, 2026 | SEC.gov ↗ |
| GRAIL, Inc. | 13G amendment | 9.6% | 4,161,584 | Aug 13, 2026 | SEC.gov ↗ |
| Beam Therapeutics Inc. | 13G amendment | 9.99% | 10,282,210 | Aug 13, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Jun 26, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 20 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (11)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private investment funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (45)
As reported in the adviser's Form ADV filed Oct 30, 2024. Funds also listed from Form D are shown above.
Fund vehicles: feeder funds and single-deal vehicles (9)
Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures